SF
Seamus Fernandez
Compare →Senior Managing Director, Pharmaceuticals Analyst at Guggenheim Securities
Financial & Wall StreetHealthcarePharmaceuticals
Seamus Fernandez is a Senior Managing Director and Pharmaceuticals Analyst at Guggenheim Securities, where he specializes in healthcare sector research, focusing on major pharmaceutical and biotechnology companies. With over 20 years of experience in the industry, he has previously held senior roles at LEERINK Partners and Cowen and Company, and he began his career in academic research at the University of Pennsylvania.
Score over time
The PunditScore after each graded call, on the panel's score bands.Hover a point to read the call. Click to pin it.
AXIS
Still open · 25
THE FRONT EDGENot resolved, so they don’t move the score.
?No market prices this claim
Sign in to read this call.
Due Jan 20, 2027 (12 months assumed)Said January 20, 2026HealthcareDrug Manufacturers
?No market prices this claim
Sign in to read this call.
Due Feb 2, 2027 (12 months assumed)Said February 2, 2026HealthcareDrug Manufacturers
?No market prices this claim
Sign in to read this call.
Due Feb 27, 2027 (12 months assumed)Said February 27, 2026HealthcareDrug Manufacturers
?No market prices this claim
Sign in to read this call.
Due Apr 29, 2027 (12 months assumed)Said April 29, 2026HealthcareDrug Manufacturers
?No market prices this claim
Seamus Fernandez upgraded Aclaris Therapeutics to a Strong-Buy rating with a 12-month price target of $12.00.
Due May 4, 2027 (12 months assumed)Said May 4, 2026MedicalPharmaceutical
?No market prices this claim
Sign in to read this call.
Due May 5, 2027 (12 months assumed)Said May 5, 2026HealthcareDrug Manufacturers
?No market prices this claim
Sign in to read this call.
Due Aug 5, 2027Said August 5, 2026Price targetEquities
?No market prices this claim
Sign in to read this call.
Due Aug 11, 2027Said August 11, 2026Price targetEquities
?No market prices this claim
Sign in to read this call.
Due Aug 12, 2027Said August 12, 2026Price targetEquities
?No market prices this claim
Sign in to read this call.
Due Aug 26, 2027Said August 26, 2026Price targetEquities
?No market prices this claim
Inventiva will reach a price target of 14.
Due Sep 15, 2027 (12 months assumed)Said September 15, 2026HealthcareDrug Manufacturers
?No market prices this claim
Eli Lilly will reach a price target of 1284.
Due Sep 18, 2027 (12 months assumed)Said September 18, 2026HealthcareDrug Manufacturers
?No market prices this claim
Amylyx Pharmaceuticals Inc will have a price target raised from $40.00 to $55.00
Due Sep 30, 2027 (12 months assumed)Said September 2026PharmaceuticalsHealthcare
?No market prices this claim
Septerna Inc will have a price target raised from $45.00 to $51.00
Due Sep 30, 2027 (12 months assumed)Said September 2026PharmaceuticalsHealthcare
?No market prices this claim
Bristol Myers Squibb Co will have a price target raised from $72.00 to $75.00
Due Sep 30, 2027 (12 months assumed)Said September 2026PharmaceuticalsHealthcare
?No market prices this claim
Eli Lilly & Co will have a price target raised from $1,163.00 to $1,183.00
Due Sep 30, 2027 (12 months assumed)Said September 2026PharmaceuticalsHealthcare
?No market prices this claim
Eli Lilly & Co will have a price target lowered from $1,168.00 to $1,163.00
Due Sep 30, 2027 (12 months assumed)Said September 2026PharmaceuticalsHealthcare
?No market prices this claim
Sign in to read this call.
Due Dec 31, 2031Said September 2023pharmaceuticalshealthcare
?No market prices this claim
Sign in to read this call.
Due Dec 31, 2031Said September 2023pharmaceuticalsanti-obesity
?No market prices this claim
Sign in to read this call.
Due Dec 31, 2031Said October 10, 2022sales forecastSotatercept
?No market prices this claim
Tenax Therapeutics Inc will have a price target raised from $34.00 to $40.00
Said September 2026PharmaceuticalsHealthcare
?No market prices this claim
Apogee Therapeutics Inc will have a price target raised from $130.00 to $160.00
Said September 2026BiotechnologyHealthcare
?No market prices this claim
Sign in to read this call.
Said May 25, 2026MedicalPharmaceutical
?No market prices this claim
Sign in to read this call.
Said March 24, 2026HealthcareDrug Manufacturers
?No market prices this claim
Sign in to read this call.
Said December 29, 2025BiopharmaceuticalWeight Loss